CARDIOVASCULAR SAFETY OF LUBELUZOLE (PROSYNAP(R)) IN PATIENTS WITH ISCHEMIC STROKE

The cardiovascular safety of lubeluzole was evaluated in patients with ischemic stroke in a double-blind, placebo-controlled trial. Forty-si x patients were randomized to receive a continuous daily infusion of l ubeluzole 5 mg (loading dose 3.75 mg over 1 h), lubeluzole 10 mg (load ing dose 7.5 mg over 1 h), or placebo for 5 days within 24 h of stroke onset. The primary measure of cardiovascular safety was the QTc inter val, derived from the continuous electrocardiogram (ECG) and measured during treatment and a 2-day follow-up. Compared with placebo, neither dosage of lubeluzole had any statistically or clinically relevant eff ects on the QTc. Neither were there any significant differences among the three treatment groups in the area under the curve for heart rate, QT interval, QT dispersion, or QT1c. Lubeluzole did not increase the frequency of ECG abnormalities. No ventricular fibrillation, ventricul ar tachycardia, or torsades de pointes were observed in any of the tre atment groups. During this trial, 3 patients in the placebo group and 2 patients in the lubeluzole 5-mg group died. There were no deaths in the lubeluzole 10-mg group. Adverse experiences were similar in all th ree treatment groups except that superficial thrombophlebitis was more frequent in the lubeluzole IO-mg group. In doses to 10 mg/day, lubelu zole has a favorable cardiovascular safety profile, as demonstrated by the lack of clinically relevant effects on heart rate, QT, QTc, and Q T1c, and it was well tolerated by patients with ischemic stroke.